创业板融资余额连增期间，融资余额增加的有513只，增幅超20%的有38只，融资余额增幅最大的是家 联科技，最新融资余额5071.71万元，其间增幅152.21%，其次是晶雪节能、菲利华，最新融资余额分别 为4743.12万元、1.67亿元，其间增幅分别为84.29%、80.53%。融资余额下降的有420只，降幅超10%的 有37只，融资余额降幅最大的是屹通新材，最新融资余额6598.37万元，其间下降30.43%，其次是鸿铭 股份、瑞晨环保，最新融资余额分别为1980.28万元、2816.10万元，其间降幅分别为27.89%、25.74%。 其间融资余额变动幅度居前个股 | 代码 | 简称 | 最新融资余额（万 | 其间增减 | 代码 | 简称 | 最新融资余额 | 其间增减 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | 元） | （%） | | | （万元） | （%） | | 301193 | 家联科 | 5071.71 | 152.21 | 300930 | 屹通新 | 6598.37 | -30.43 | | | 技 | | | | ...

Core Viewpoint - The company, Opcon Vision, is attempting to regain its market position in the corneal reshaping lens (OK lens) sector through the acquisition of a controlling stake in Shangyue Qicheng Hospital Management Co., Ltd for 334 million yuan, funded partly by redirected fundraising from a previous project that has seen slow progress [2][3][4]. Group 1: Acquisition Details - The acquisition involves purchasing 75% of Shangyue Qicheng, which has a valuation of 445 million yuan, representing a significant premium of over 7 times its book value [4]. - Shangyue Qicheng's core asset is the fully-owned subsidiary, Xingcheng Eye Hospital, which focuses on vision correction and related services, with approximately 40% of its business in refractive medical services and 14% related to OK lens [3][4]. - The acquisition is expected to enhance Opcon Vision's service density and market competitiveness, leveraging synergies between medical and optical services [3]. Group 2: Financial Performance and Market Challenges - Opcon Vision reported a revenue of 1.814 billion yuan in 2024, a modest growth of 4.4%, but a decline in net profit by 14.16% to 572 million yuan, marking the worst performance in recent years [7]. - The decline in sales of OK lenses, which generated 760 million yuan in revenue, is attributed to high-end consumer fatigue, competition from alternative products, and an overall increase in market competition [7][9]. - The market for OK lenses is becoming increasingly competitive, with over 20 companies now registered to produce these products, leading to a significant drop in profit margins [9][10]. Group 3: Strategic Outlook - The company aims to implement a dual strategy of "full optical products + all-age optical services" to drive growth, while being cautious about new site openings due to current market conditions [8][10]. - Future plans include evaluating potential acquisition targets in the optical service sector to support both organic growth and external expansion [10].

Group 1 - The stock price of Chunli Medical (688236) closed at 18.4 yuan on July 9, 2025, with a slight decrease of 0.05% and a turnover rate of 0.65% [1] - The trading volume was 18,900 shares, resulting in a total transaction amount of 34.8274 million yuan [1] Group 2 - On July 9, the net inflow of main funds into Chunli Medical was 415,000 yuan, accounting for 1.19% of the total transaction amount [2] - The net outflow of speculative funds was 3.7303 million yuan, representing 10.71% of the total transaction amount [2] - Retail investors contributed a net inflow of 3.3153 million yuan, which is 9.52% of the total transaction amount [2]

Group 1 - The article highlights the geopolitical dilemma faced by the EU as it attempts to navigate between the US and China, with the EU trying to establish a trade agreement with the US while simultaneously managing its relationship with China [1][2][4] - The EU has imposed trade barriers against Chinese products, citing "unfair competition," but these measures have led to retaliatory actions from China, including investigations into EU products such as pork and brandy [1][5] - The EU's economic dependence on China limits its ability to exert pressure, as highlighted by the fact that many European countries still rely heavily on Chinese industrial materials [8][9][11] Group 2 - The EU's recent measures to restrict Chinese participation in public procurement for medical devices are framed as necessary for "fair competition," but these actions have prompted China to respond with equivalent restrictions [5][7] - Despite the EU's criticisms of China's trade practices, the economic interdependence between the two regions constrains the EU's capacity to apply significant pressure on China [9][11] - The EU is also facing challenges from the US, with expected increases in export tariffs, which may compel the EU to adopt a tougher stance on China as part of negotiations with the US [7][8]

丨证券研究报告丨 戴清 胡飞 请阅读最后评级说明和重要声明 市场策略丨专题报告 [Table_Title] 复盘供给侧改革："反内卷"如何催生产能出清 主升浪 报告要点 [Table_Summary] 近期政策再次提及要规范企业低价无序竞争，推动落后产能有序退出，我们复盘历史类似的政 策推动供给端出清案例，结果发现，在政策推动下的供给端出清，第一阶段的行情起于政策预 期，后续主升浪则需行业格局改善配合。落地到本轮"反内卷"政策，策略应对上，关注两条 主线，一是本身供给端出清时间比较久，供需格局有望改善即自然出清的行业；二是或受益于 政策预期推动加速出清的行业。 分析师及联系人 [Table_Author] SAC：S0490524010002 SFC：BTR264 %% %% %% %% research.95579.com 1 [Table_Summary2] 政策信号明确：规范企业低价无序竞争，推动落后产能有序退出 政策信号明确，整治"内卷式"竞争。近年来，市场竞争"内卷化"之所以愈演愈烈，其核心 症结在于许多行业长期累积的产能过剩。当供给远大于需求，存量市场的博弈便不可避免地异 化为内卷。这种恶性竞争不 ...

Group 1: Company Performance - Northern Rare Earth expects a net profit of 900 million to 960 million yuan for the first half of 2025, representing a year-on-year increase of 1882.54% to 2014.71% [1] - Muyuan Foods anticipates a net profit of 10.5 billion to 11 billion yuan for the first half of 2025, reflecting a year-on-year growth of 924.6% to 973.39% [2] - Hongta Securities projects a net profit of 651 million to 696 million yuan for the first half of 2025, indicating a year-on-year increase of 45% to 55% [3] Group 2: Business Developments - Dazhihui clarifies that it has not engaged in businesses related to "stablecoins," "virtual asset trading," or "cross-border payments," following a significant stock price fluctuation [4] - Bluetech announces a share transfer agreement where its actual controller will change, with the Ma'anshan Municipal Government becoming the actual controller after the transfer of 18% of shares [5] Group 3: Industry Trends - Jiangsu Electric Power reports a 5.01% year-on-year increase in electricity generation for the first half of 2025 [6] - Jin'an Guoji anticipates a non-recurring net profit growth of 4700% to 6300% for the first half of 2025 [6] - New Beiyang expects a non-recurring net profit growth of 650% to 720% for the first half of 2025 [6]

上交所官网显示，7月8日，深圳北芯生命科技股份有限公司（以下简称"北芯生命"）科创板IPO对外披露二轮问询回复意见。作为一家选 用科创板第五套上市标准上市的企业，报告期内，北芯生命净利正在逐年减亏。不过，公司核心技术人员离职、销售费用率高于同行、 募投项目能否消化等问题在二轮问询中受到上交所的关注。 核心技术人员离职 报告期内，北芯生命存在核心技术人员离职的情况。 招股书显示，北芯生命是一家专注于心血管疾病精准诊疗创新医疗器械研发、生产和销售的国家高新技术企业，致力于开发为心血管疾 病诊疗带来变革的精准解决方案。截至招股说明书签署日，公司累计向市场推出9个产品，在研产品共有8个，覆盖IVUS系统、FFR系 统、血管通路产品、冲击波球囊治疗系统及电生理解决方案五大产品类别。 研发能力是衡量科创板企业质地的一大因素。2022—2024年，北芯生命研发人员数量持续下滑，分别为151人、136人及109人，且存在核 心技术人员离职的情况。2024年8月，公司核心技术人员李恒伟离职。离职后，公司核心技术人员分别为宋亮、李林、张鹏涛。 上交所在二轮问询中也关注了这一情况，要求公司结合报告期内核心技术人员变化、研发团队的变 ...

Group 1 - The core business of the company is the research, development, production, and sales of innovative medical devices in the field of electrophysiological interventional diagnosis and ablation treatment [2] - The company aims to provide globally competitive integrated solutions for diagnosis and ablation treatment, centered around precise interventional navigation [2] - The company has a range of products including the Columbus 3D cardiac electrophysiology mapping system and various disposable catheters and ablation devices [2] Group 2 - As of the latest financial report for Q1 2025, the company achieved a revenue of 104 million yuan, representing a year-on-year increase of 16.77%, and a net profit of 17.87 million yuan, up 328.63% [3] - The company's gross profit margin stands at 60.56% [3] - The company's current price-to-earnings (PE) ratio is 140.53, significantly higher than the industry average of 51.36 [3]

Company Overview - Weisi Medical's closing price on July 9 was 45.03 yuan, down 1.27%, with a rolling PE ratio of 38.02 times and a total market value of 4.313 billion yuan [1] - The company ranks 80th in the medical device industry, which has an average PE ratio of 51.36 times and a median of 37.22 times [1] Financial Performance - For the first quarter of 2025, Weisi Medical reported revenue of 95.9127 million yuan, a year-on-year increase of 9.40% [1] - The net profit for the same period was 33.2201 million yuan, reflecting a year-on-year growth of 52.71% [1] - The sales gross margin stood at 66.65% [1] Shareholding Structure - As of the first quarter of 2025, five institutions held shares in Weisi Medical, including three other entities and two funds, with a total holding of 10.7452 million shares valued at 364 million yuan [1]

7月9日，威高血净今日收盘37.69元，下跌1.10%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到33.88倍，总市值155.05亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均51.36倍，行业中值37.22倍，威高血净排 名第71位。 股东方面，截至2025年5月19日，威高血净股东户数59754户，较上次增加59736户，户均持股市值35.28 万元，户均持股数量2.76万股。 山东威高血液净化制品股份有限公司的主营业务为血液净化医用制品的研发、生产和销售。公司主要产 品包括血液透析器、血液透析管路、血液透析机以及腹膜透析液，分别围绕血液透析和腹膜透析领域， 辅以透析配套产品的销售，是国内产品线最为丰富的血液净化医用制品厂商之一。2022年公司在国内血 液透析器领域的市场份额占比为32.5%，位列全行业第一；在国内血液透析管路领域的市场份额占比为 32.8%，位列全行业第一；2022年公司获授权独家销售的威高泰尔茂品牌腹膜透析液在国内腹膜透析液 领域的市场份额占比为3.6%，位列全行业第五。 最新一期业绩显示，2025年一季报，公司实现营业收入8.96亿元，同比6.44% ...